43 results
8-K
EX-99.1
VTGN
Vistagen Therapeutics Inc.
3 May 18
VistaGen Therapeutics Receives Notice of Allowance for Japanese Patent regarding Methods of Production for AV-101
12:00am
and SNRIs for depression, most of which, if effective, take many weeks to achieve therapeutic benefits. AV-101 targets glutamate, the most prevalent
8-K
EX-99.1
VTGN
Vistagen Therapeutics Inc.
26 Oct 18
Entry into a Material Definitive Agreement
4:21pm
another potentially safe, fast-acting, new generation mechanism of action treatment in play, in addition to AV-101 with its NMDAR GlyB and AMPAR targets
8-K
EX-99.1
VTGN
Vistagen Therapeutics Inc.
6 Apr 23
Vistagen Receives New European Patent for AV-101
4:31pm
that AV-101 activity appears to be specific to the GlycineB site, with virtually no off-target activity in a panel of more than 50 receptor targets
8-K
EX-99.1
VTGN
Vistagen Therapeutics Inc.
13 Jul 23
Vistagen Receives Notice of Allowance for AV-101 Canadian Patent for Treatment of Dyskinesia Related to Levodopa Therapy for Parkinson’s Disease
4:35pm
of AV-101 or 7-Cl-KYNA to off-site targets was identified by an extensive receptor screening study. Moreover, in all clinical trials completed to date, AV
8-K
EX-99
VTGN
Vistagen Therapeutics Inc.
1 Jun 20
VistaGen and Nuformix Announce Agreement to Develop Novel Patentable Cocrystalline Forms of AV-101 for Treatment of Multiple CNS Conditions
4:53pm
, and suicidal ideation.
About AV-101
AV-101 (4-Cl-KYN) targets the NMDAR (N-methyl-D-aspartate receptor), an ionotropic glutamate receptor in the brain
8-K
EX-99
jge76g3d
13 Feb 20
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
4:39pm
8-K
EX-99.1
cubbhj3 u84oh7m
6 Apr 18
VistaGen Therapeutics Initiates Phase 2 Study of AV-101 for Major Depressive Disorder
12:00am
8-K
EX-99.1
fhs7t ovt
25 Apr 24
Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
7:18pm
8-K
EX-99.1
4te xudz00pxa2
3 Jan 24
Vistagen Receives Notice from European Patent Office of Intention to Grant Patent for AV-101 to Treat Neuropathic Pain
5:09pm
8-K
EX-99.1
jnpkdkpi5lg 2nsmjhb
14 Aug 18
Other Events
2:32pm
8-K
EX-99
r736tgd
14 Aug 20
VistaGen Therapeutics Reports Fiscal 2021 First Quarter Financial Results and Highlights CNS Pipeline and Business Progress
5:24pm
8-K
EX-99
279ts4
13 Feb 20
VistaGen Therapeutics Reports Fiscal 2020 Third Quarter Financial Results and Provides CNS Pipeline Overview
4:39pm
8-K
EX-99.1
juxepyt712k5
30 Jun 20
VistaGen Therapeutics Reports Fiscal Year 2020 Results and Provides CNS Pipeline Update
4:16pm
8-K
EX-99
4nslog3kwh
29 Jun 21
VistaGen Therapeutics Reports Fiscal Year 2021 Financial Results and Provides Corporate Update
4:09pm
424B5
04sjnhg3l87giz
3 Oct 23
Prospectus supplement for primary offering
4:40pm
424B5
dyndbmbw
14 May 21
Prospectus supplement for primary offering
4:06pm